TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.

Autor: Cantero D; Department of Pathology (Neuropathology) and Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain., Mollejo M; Department of Pathology, Virgen de la Salud Hospital, Toledo, Spain., Sepúlveda JM; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain., D'Haene N; Department of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium., Gutiérrez-Guamán MJ; Department of Pathology (Neuropathology) and Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain., Rodríguez de Lope Á; Department of Neurosurgery, Virgen de la Salud Hospital, Toledo, Spain., Fiaño C; Department of Pathology, Alvaro Cunqueiro Hospital, Vigo, Spain., Castresana JS; Department of Biochemistry and Genetics, University of Navarra School of Sciences, Pamplona, Spain., Lebrun L; Department of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium., Rey JA; IdiPaz Research Unit, La Paz University Hospital, Madrid, Spain., Salmon I; Department of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium., Meléndez B; Department of Pathology, Virgen de la Salud Hospital, Toledo, Spain.; Department of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium., Hernández-Laín A; Department of Pathology (Neuropathology) and Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain.

Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2020 Jan 24; Vol. 2 (1), pp. vdz059. Date of Electronic Publication: 2020 Jan 24 (Print Publication: 2020).